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Background: The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks
in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at
24 weeks.
Methods: 365 treatment-naïve patients with T2DM (HbA1c 7.0%–10.0%) were treated with saxagliptin 2.5 mg q.A.M.,
saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P.
M., or placebo. After week 24, patients in all groups were eligible for titration to saxagliptin 10 mg based on HbA1c
≥7%, and all unrescued placebo patients began blinded metformin 500 mg/day. Rescue with open-label metformin
was available for patients with inadequate glycemic control.
Results: At week 24, placebo-subtracted mean HbA1c reduction from baseline (LOCF) was significantly greater in
the saxagliptin treatment groups vs placebo, and remained greater through week 76. Serious adverse events (AEs)
and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed
hypoglycemia was low across all treatment groups (saxagliptin-treated, 2 [0.7]; control, 1 [1.4]).
Conclusions: In treatment-naïve patients with T2DM, saxagliptin monotherapy demonstrated statistically significant
improvement in HbA1c compared with placebo at 24 weeks and was generally well tolerated for up to 76 weeks.
Trial registration: ClinicalTrials.gov Identifier: NCT00316082
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After initiation of therapy, patients with type 2 diabetes
mellitus (T2DM) are likely to require pharmacothera-
peutic management for the remainder of their lives.
Understanding the long-term efficacy and safety profiles
of newer antidiabetic medications is necessary for opti-
mizing treatment regimens over time. Incretin-based
therapies, such as dipeptidyl peptidase-4 (DPP-4) inhibi-
tors, are a class of recently developed antidiabetic agents
for which long-term safety data are only now becoming
available [1].* Correspondence: bob.frederich@bms.com
1Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543,
USA
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reproduction in any medium, provided the orSaxagliptin is a potent, selective DPP-4 inhibitor
approved as an adjunct to diet and exercise to improve
glycemic control in adults with T2DM [2]. As monother-
apy, saxagliptin 2.5, 5, and 10 mg led to statistically sig-
nificant improvements in glycemic indices versus placebo
at week 24, and was generally well tolerated in treatment-
naïve patients with T2DM. Hypoglycemic events were
comparable between saxagliptin treatment groups and
placebo, and there were no increases in weight [3]. Cur-
rently, long-term efficacy and safety data for saxagliptin
as add-on therapy to metformin [4], a sulfonylurea [5], or
a thiazolidinedione [6], or as initial combination therapy
with metformin [7], have been published, but long-term
data have not been published for saxagliptin monotherapy
at approved doses of 2.5 and 5 mg.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a second treatment-naïve population. The current
study was designed to demonstrate the efficacy and
safety of saxagliptin monotherapy when used as a fixed-
dose treatment and with titration in the initial treatment
of hyperglycemia in patients with T2DM inadequately
controlled with diet and exercise. The comparator to
week 24 was placebo, converting thereafter to metformin
500 mg to week 76. This study also explored A.M. and
P.M. dosing and early titration of saxagliptin 2.5 to 5 mg
(approved doses) in the first 24 weeks. In order to evalu-
ate whether uptitration from 5 mg to 10 mg provides
any further improvement in glycemic control and to fur-
ther characterize safety with the 10-mg dose, patients in
all saxagliptin groups could be titrated to 10 mg in
weeks 24 to 76 based on prespecified glycated
hemoglobin (HbA1c) criteria. Data on time of day at
which dosing occurs and titration are important to phy-




Patients were recruited from 72 sites in the United States,
Russia, India, and Taiwan. Inclusion and exclusion criteria
were similar to those used and reported in the other saxa-
gliptin monotherapy study [3]. Briefly, patients 18 to
77 years of age with T2DM and inadequate glycemic
control (HbA1c at screening 7.0%− 10.0%) with diet and
exercise alone, body mass index (BMI) ≤40 kg/m2, and
C-peptide ≥1.0 ng/mL were eligible. All patients were
treatment naïve, defined as those who had never
received medical treatment for diabetes (insulin and/or
oral antihyperglycemic agents) or had received medical
treatment for diabetes for a total of <6 months since
original diagnosis. Exclusion criteria included symptoms
of poorly controlled diabetes; history of diabetic ketoaci-
dosis or hyperosmolar non-ketotic coma; insulin therapy
within 1 year of screening; cardiovascular event within
6 months prior to study entry or New York Heart As-
sociation stage III/IV congestive heart failure (CHF)
and/or known left ventricular ejection fraction ≤40%;
significant renal history, alcohol or drug abuse within
the previous year; treatment with potent CYP3A4 inhi-
bitors or inducers; immunocompromised individuals;
active liver disease or clinically significant abnormal
results on hepatic, renal, endocrine, metabolic, or
hematologic screening tests.
This study was performed in accordance with Good
Clinical Practice as defined by the International Confer-
ence on Harmonisation and the ethical principles set
forth in the Declaration of Helsinki. Patients freely pro-
vided written informed consent. The study protocol,
amendments, and patient informed consent wereapproved by the institutional review board/independent
ethics committee for each participating site prior to
study initiation.
Study design
This was a 24-week, phase 3, randomized, 5-arm,
parallel-group, double-blind, placebo-controlled, multi-
center trial with an extension to 76 weeks. The 24-week
short-term period was designed to assess the efficacy
and safety of saxagliptin monotherapy as 2.5 mg q.A.M.
without titration, 2.5 mg q.A.M. with titration, 5 mg q.A.
M., and 5 mg q.P.M. The 52-week extension included
patients who either completed the short-term, double-
blind period or were rescued due to lack of glycemic
control. Rescue medication was also available in the
long-term extension based on predefined criteria. The
long-term extension was designed to assess long-term
safety and glycemic parameters for each saxagliptin regi-
men. Eligible patients were instructed on diet and exer-
cise in accordance with the American Diabetes
Association (ADA) or corresponding guidelines in each
country. Following completion of the lead-in period,
patients were randomized (1:1:1:1:1) to saxagliptin
2.5 mg q.A.M., saxagliptin 2.5 mg with possible titration
to 5 mg q.A.M. (2.5/5 mg q.A.M.), saxagliptin 5 mg q.A.
M., saxagliptin 5 mg q.P.M., or placebo. In patients ran-
domized to saxagliptin 2.5/5 mg q.A.M., saxagliptin was
initiated at 2.5 mg and titrated to 5 mg if mean fasting
plasma glucose (FPG) was ≥150 mg/dL at week 4, ≥140
and ≤220 mg/dL at week 8, or ≥126 and ≤200 mg/dL at
weeks 12 and 24.
Patients with inadequate glycemic control during the
short-term period were eligible for add-on, open-label
metformin rescue therapy dosed beginning with 500 mg/
day and titrated as tolerated to a maximum of 2000 mg/
day. Rescue criteria for lack of glycemic control based
upon FPG during the short-term period became pro-
gressively more strict at week 6 (>240 mg/dL); week 8
(>220 mg/dL); and weeks 12, 16, 20, and 24 (>200 mg/
dL). Patients rescued from the short-term period were
reported as early discontinuations for lack of efficacy
prior to entering the long-term extension.
Patients who completed or were rescued during the
short-term period were eligible to enter the 52-week
long-term extension. During the long-term extension,
patients who had completed all visits and had not met
hyperglycemia rescue criteria in the short-term period
were allowed to titrate up to a maximum saxagliptin
dose of 10 mg if HbA1c was >8.0% at weeks 30, 37, and
50 or >7.5% at week 63. Patients who had received pla-
cebo in the short-term period and were not rescued
were switched to blinded metformin 500 mg in the long-
term extension. Titration of blinded metformin was pro-
hibited. Patients who met hyperglycemia rescue criteria
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domized dose and treatment assigned throughout the
long-term extension, but received open-label metformin,
which could be titrated to a maximum of 2000 mg/day,
in addition to their study medication. Patients with lack
of glycemic control during the long-term treatment
period (HbA1c >8.0% at weeks 30, 37, and 50 or >7.5%
at week 63) were also eligible for rescue with open-label
metformin 500 mg titrated as tolerated to a maximum
of 2000 mg/day. Patients in the comparator group were
defined as the “placebo group” up to week 24 and as the
“control group” once they entered the long-term
extension.
Study endpoints and assessments
The primary efficacy endpoint was the change from
baseline HbA1c at week 24 for the saxagliptin 2.5 mg q.
A.M., 2.5/5 mg q.A.M., 5 mg q.A.M., and placebo
groups. Secondary endpoints for all treatment groups in
the short-term period were change from baseline FPG,
the proportion of patients achieving HbA1c <7.0%, and
change from baseline in area under the curve (AUC)
from 0 to 180 minutes for postprandial glucose (PPG-
AUC) response to an oral glucose tolerance test
(OGTT), and for the saxagliptin 5 mg q.P.M. group,
change from baseline HbA1c at week 24.
Glycemic parameters evaluated for each saxagliptin
treatment group in the 52-week long-term extension
included time to rescue for failing to achieve prespeci-
fied glycemic targets or discontinuations due to lack of
efficacy; change from baseline HbA1c, FPG, and PPG-
AUC over time; and change in HbA1c from first titration
in long-term extension to 13 weeks post–first titration.
Safety and tolerability assessments included adverse
events (AEs), serious AEs (SAEs), related AEs, disconti-
nuations from study medication due to AEs, and deaths.
Laboratory values, electrocardiograms, vital signs, phys-
ical examinations, and body weight were also assessed.
Data analysis
For the short-term period, a primary efficacy analysis
was performed for the endpoint of change in HbA1c
from baseline to week 24 comparing the saxagliptin q.A.
M. treatment groups to placebo, with missing data
imputed on a last-observation-carried-forward (LOCF)
basis. A two-step, parallel gatekeeping methodology was
used to preserve the overall type I error rate at the 0.05
level [8]. As a first step, comparisons were made be-
tween the saxagliptin 2.5 mg q.A.M. and 5 mg q.A.M.
treatment groups versus the placebo group. If either sax-
agliptin group showed significance for HbA1c at the
α= 0.027 level versus placebo, the second step compari-
son would use the same α level; if both first-step com-
parisons reached significance, α= 0.05 would be used.The second comparison was the saxagliptin 2.5/5 mg q.
A.M. titrated group versus placebo. Assuming a standard
deviation (SD) of 1.1%, 62 patients per treatment group
would provide 90% power to detect a difference in
means of 0.7% between saxagliptin 2.5 mg q.A.M. or
5 mg q.A.M versus placebo.
The statistical testing of the secondary efficacy end-
points proceeded in a sequential manner, to control the
type I error rate within each treatment group at the 0.05
level. The first secondary endpoint was the change in
HbA1c from baseline to week 24 in the saxagliptin 5 mg
q.P.M. treatment group. For all treatment groups, sec-
ondary endpoints were the change in FPG from baseline
to week 24, the percentage of patients achieving HbA1c
<7.0% at week 24, and the change from baseline to week
24 in AUC from 0 to 180 minutes for PPG response to
an OGTT. Mean changes from baseline to week 24
(LOCF) were compared between each investigative treat-
ment group and the placebo group based on adjusted
means generated using an analysis of covariance
(ANCOVA) model. Within this framework, point esti-
mates and 95% confidence intervals (CIs) were calcu-
lated for the mean changes from baseline within each
treatment group, as well as for the difference in mean
change from baseline between each investigative treat-
ment group and the placebo group. The percentages of
patients achieving HbA1c <7.0% at week 24 (LOCF)
were compared between each investigative treatment
group and the placebo group using the Fisher exact test.
Patients in the placebo group began receiving active
therapy with metformin as they entered the long-term
extension. Changes from baseline HbA1c during the
whole study period were reported. For these longer-term
analyses, a repeated-measures analysis was performed, as
it more appropriately addresses missing data compared
with the LOCF analysis in the long-term extension, in
which fewer data are available for analysis due to rescue
or study discontinuation.
A total of 50 patients (14% of the randomized patients)
had OGTT samples that were rendered invalid when in-
correct quantities of glucose were administered. Patients
were to begin administration of 75 g of oral glucose so-
lution at time 0 minutes during the OGTT. However,
bottles containing more than 75 g of oral glucose solu-
tion were shipped and administered at certain study sites
in Russia. At those sites, patients who were dispensed an
amount in excess of the prespecified 75 g of oral glucose
solution were not included in any analysis of OGTT
parameters.
Safety analyses were performed using all data in the
short-term period and long-term extension. AEs were
tabulated and classified according to the Medical Dic-
tionary for Regulatory Activities (MedDRA) version 11.1
at the preferred term level and grouped by system organ
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from other AEs; confirmed hypoglycemia was defined by




Patient disposition for the 24-week, short-term period
and long-term extension is illustrated in Figure 1. A total
of 869 patients completed the informed consent cover-
ing all phases of the study and were screened; 394
entered the lead-in period. Following a 2-week, single-
blind, dietary and exercise placebo lead-in period, 365
patients were randomized (74, 74, 71, 72, and 74 patients
in the saxagliptin 2.5 mg q.A.M., 5 mg q.A.M., 2.5/5 mg
q.A.M., and 5 mg q.P.M., and placebo groups, respect-
ively) and treated with double-blind therapy; 272
patients completed 24 weeks of short-term treatment
without rescue. Of the 311 patients who entered the
long-term extension (including 266 of the 272 short-
term non-rescued completers), 231 completed the study
(76 weeks), 147 without being rescued. Total completion
and completion without rescue proportions were highest
in the saxagliptin 5 mg q.A.M. group, and lowest in the
2.5 mg q.A.M. group, with the 3 remaining groups com-
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Figure 1 Patient disposition short-term period (week 24) and long-te
were rescued in short-term period or long-term extension period. Rescued
not enter lead-in period but was directly randomized to double-blind treat
patient in the placebo group completed week 24, but discontinued treatmduring the long-term extension from the randomized
dose was numerically higher in the groups randomized
to saxagliptin 5 mg (17.9%–26.4%) than in those rando-
mized to saxagliptin 2.5 mg (9.3%–13.7%). In conse-
quence, by the end of the study even in the groups in
which the initial randomized dose was 2.5 mg (saxaglip-
tin 2.5 mg q.A.M. and 2.5/5 mg q.A.M.), nearly all of the
patients were taking saxagliptin 5 or 10 mg.
Among patients who completed the short-term period,
42.6%, 82.1%, 68.6%, and 73.6% of patients were eventu-
ally titrated to 10 mg in the saxagliptin 2.5 mg q.A.M.,
5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M. groups,
respectively. Most of the patients in the saxagliptin 2.5/
5 mg q.A.M. group had already been titrated to 5 mg by
week 24.
Mean duration of exposure ranged from 54.6 weeks
(2.5 mg q.A.M.) to 62.2 weeks (5 mg q.A.M.) across the
saxagliptin treatment groups and was 58.8 weeks in the
control group. The median duration of exposure to
study medication was approximately 75 weeks across all
treatment groups.
Patient demographics
Patient demographic characteristics were generally
balanced across the randomized treatment groups. How-
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rm extension (week 76). Rescued patients include all patients who
patients may later have discontinued from the study.*One patient did
ment. †One patient in the saxagliptin 5 mg q.P.M. group and one
ent (lost to follow-up and poor compliance, respectively).
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men was highest in the saxagliptin 2.5/5 mg q.A.M.
group (52.1%) and lowest in the saxagliptin 2.5 mg q.A.
M. group (33.8%). The mean body weight of patients re-
ceiving placebo was 85.4 kg, and ranged from 83.3 to
86.5 kg among patients receiving saxagliptin. Median
baseline HbA1c for all of the saxagliptin treatment
groups was 7.8% or 7.9% whereas the median HbA1c for
the placebo group was 7.6%. Overall 70% of patients
were white and 23% were Asian. The mean duration of
diabetes was 1.7 years, and mean baseline HbA1c was
7.9% for the entire study population. This unselected pa-
tient population demonstrated a substantial prevalence
of risk factors for cardiovascular (CV) events at baseline.
Nine percent had prior CHF history, 13% had coronary
artery disease history, and 5% had prior myocardial
infarction. A majority of patients had a history of hyper-
tension (58%), and a substantial minority had a history
of obesity (46%), hypercholesterolemia (33%), mixed dys-
lipidemia (18%), and tobacco use (25%).Table 1 Baseline demographic and clinical characteristics
Characteristic SAXA 2.5 mg q.A.M. SAXA 5 m
(n= 74) (n =
Age, years, mean (SD) 55.2 (10.44) 54.7 (9
Age ≥65 years, n (%) 16 (21.6) 12 (1
Gender, n (%)
Male 25 (33.8) 38 (5
Female 49 (66.2) 36 (4
Race, n (%)
White 50 (67.6) 49 (6
Black/African American 5 (6.8) 5 (6
Asian 18 (24.3) 20 (2
Other 1 (1.4) 0
Weight, kg, mean (SD) 83.8 (16.70) 86.5 (2
BMI, kg/m2, mean (SD) 30.4 (4.84) 31.0 (5
Duration of diabetes, years, mean (SD) 1.2 (1.6) 1.7 (2
HbA1c, %, mean (SD) 8.0 (0.8) 8.0 (0
<8.0%, n (%) 40 (54.1) 40 (5
≥8.0% to< 9.0%, n (%) 23 (31.1) 27 (3
≥9.0%, n (%) 11 (14.9) 7 (9
FPG, mg/dL, mean (SD) 158 (33.0) 162 (3
Hypertension, n (%) 40 (54.1) 36 (4
Hypercholesterolemia, n (%) 25 (33.8) 22 (2
Mixed dyslipidemia, n (%) 13 (17.6) 14 (1
CHF, n (%) 6 (8.1) 8 (1
Coronary artery disease, n (%) 9 (12.2) 8 (1
Prior MI, n (%) 4 (5.4) 2 (2
BMI: body mass index; CHF: congestive heart failure; FPG: fasting plasma glucose; H
standard deviation.Change in glycemic parameters
Short-term period (week 24)
The mean adjusted changes from baseline HbA1c and
FPG, the percentage of patients achieving HbA1c <7%,
and mean adjusted changes from baseline PPG-AUC
during the short-term period are presented in Table 2.
There were reductions from baseline HbA1c (LOCF) in
all saxagliptin treatment groups (−0.61% to −0.71%) and
a smaller reduction in the placebo group (−0.26%)
(Figure 2). All reductions with saxagliptin were signifi-
cantly greater than with placebo (P= 0.002, P= 0.006,
P= 0.012, and P= 0.016 for saxagliptin 2.5 mg q.A.M.,
5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M., respect-
ively). Reductions from baseline FPG (LOCF) of −10.7 to
−12.5 mg/dL were observed in the saxagliptin morning
dosing groups. All were significantly greater than with
placebo (P= 0.020, P= 0.027, and P= 0.013 for saxaglip-
tin 2.5 mg q.A.M., 5 mg q.A.M., and 2.5/5 mg q.A.M.,
respectively). The reduction in FPG in the saxagliptin
5 mg q.P.M. treatment group, −7.9 mg/dL, did not reachg q.A.M. SAXA 2.5/5 mg q.A.M. SAXA 5 mg q.P.M. Placebo
74) (n = 71) (n = 72) (n = 74)
.71) 54.3 (10.93) 55.1 (10.35) 55.6 (10.32)
6.2) 12 (16.9) 11 (15.3) 13 (17.6)
1.4) 37 (52.1) 33 (45.8) 35 (47.3)
8.6) 34 (47.9) 39 (54.2) 39 (52.7)
6.2) 54 (76.1) 48 (66.7) 53 (71.6)
.8) 2 (2.8) 8 (11.1) 4 (5.4)
7) 14 (19.7) 16 (22.2) 17 (23)
1 (1.4) 0 0
0.71) 85.4 (17.25) 83.3 (19.10) 85.4 (14.40)
.23) 30.6 (4.72) 29.6 (5.37) 31.1 (4.54)
.4) 2.0 (2.9) 2.0 (5.2) 1.7 (2.8)
.9) 8.0 (1.1) 7.9 (0.9) 7.8 (1.0)
4.1) 37 (52.1) 38 (52.8) 47 (63.5)
6.5) 18 (25.4) 24 (33.3) 15 (20.3)
.5) 16 (22.5) 10 (13.9) 12 (16.2)
5.6) 171 (51.8) 160 (44.6) 160 (46.2)
8.7) 48 (67.6) 41 (56.9) 47 (63.5)
9.7) 32 (45.1) 23 (31.9) 17 (23.0)
8.9) 15 (21.1) 13 (18.1) 9 (12.2)
0.8) 7 (9.9) 4 (5.6) 7 (9.5)
0.8) 15 (21.1) 8 (11.1) 9 (12.2)
.7) 5 (7.0) 4 (5.6) 4 (5.4)
bA1c: glycated hemoglobin; MI: myocardial infarction; SAXA: saxagliptin; SD:
Table 2 Changes in glycemic parameters from baseline to week 24 (LOCF)
SAXA 2.5 mg q.A.M. SAXA 5 mg q.A.M. SAXA 2.5/5 mg q.A.M. SAXA 5 mg q.P.M. Placebo
(n= 74) (n = 74) (n = 71) (n = 72) (n = 74)
HbA1c (%)
n 67 69 69 70 68
BL, mean (SE) 8.0 (0.11) 7.9 (0.11) 8.0 (0.13) 7.9 (0.11) 7.8 (0.11)
Week 24 mean (SE) 7.3 (0.11) 7.3 (0.13) 7.4 (0.14) 7.3 (0.12) 7.6 (0.14)
Adj change from BL, mean (SE) −0.71 (0.103) −0.66 (0.102) −0.63 (0.102) −0.61 (0.101) −0.26 (0.103)
Difference from placebo (SE) −0.45 (0.146) −0.40 (0.145) −0.37 (0.145) −0.35 (0.144)
P-value vs placebo 0.002* 0.006* 0.012* 0.016*
FPG (mg/dL)
n 70 71 71 71 71
BL, mean (SE) 157 (4.0) 162 (4.2) 171 (6.2) 160 (5.3) 159 (5.4)
Week 24 mean (SE) 147 (3.8) 151 (5.9) 155 (5.9) 152 (5.9) 163 (6.3)
Adj change from BL, mean (SE) −11 (4.5) −11 (4.5) −13 (4.5) −8 (4.5) 3 (4.5)
Difference from placebo (SE) −15 (6.3) −14 (6.3) −16 (6.3) −11 (6.3)
P-value vs placebo 0.020* 0.027* 0.013* 0.076
Patients achieving HbA1c <7% (%) 35.8 44.9 43.5 38.6 35.3
Difference from placebo (%) 0.5 9.6 8.2 3.3
P-value vs placebo 1.0000 0.2968 0.3832 †
PPG–AUC (mg•min/dL)
n 48 48 47 43 47
BL, mean (SE) 47432 (1496.6) 50417 (1561.5) 50032 (1684.7) 47078 (1941.9) 47640 (1759.7)
Week 24 mean (SE) 39798 (1347.0) 41562 (1489.3) 41745 (1739.2) 41530 (1962.7) 44861 (1854.7)
Adj change from BL, mean (SE) −8014 (1246.9) −8218 (1249.1) −7781 (1261.0) −6048 (1318.2) −3088 (1259.7)
Difference from placebo (SE) −4927 (1771.1) −5130 (1776.4) −4694 (1784.3) −2961 (1821.5)
P-value vs placebo † † † †
Randomized patients data set.
*Statistically significant at prespecified level.
†P-values only presented when permitted by sequential testing procedure.
Adj: adjusted; BL: baseline; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; PPG-AUC: postprandial glucose–area under the curve; SAXA: saxagliptin; SE:
standard error.
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proportions of patients achieving an HbA1c <7% were
slightly larger for all saxagliptin treatment groups rela-
tive to placebo, the differences were not statistically sig-
nificant. Consistent mean reductions from baseline in
PPG-AUC were observed for all saxagliptin groups com-
pared with placebo. However, the placement of this end-
point in the sequential testing procedure prohibited
interpretation of statistical significance.
Body weight
Overall, there were reductions in mean body weight in
all treatment groups. The mean (SE) change from base-
line body weight (LOCF) was −0.3 kg (0.35), –0.9 kg
(0.31), –0.9 kg (0.41), –0.4 kg (0.36), and −1.3 kg (0.40)
for saxagliptin 2.5 mg q.A.M., 5 mg q.A.M., 2.5/5 mg q.
A.M., 5 mg q.P.M., and placebo treatment groups,
respectively.Long-term extension (week 76)
Upon entry to the long-term extension, all patients in
the placebo group who did not receive rescue therapy
were placed on blinded metformin for the duration of
the study.
By 13 weeks post-titration, most patients in the saxa-
gliptin 5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M.
treatment groups had been titrated to saxagliptin 10 mg,
while most of the patients in the saxagliptin 2.5 mg q.A.
M. treatment group had been titrated to saxagliptin
5 mg. Mean changes in HbA1c from time of first titra-
tion in the long-term extension to 13 weeks after titra-
tion were small and inconsistent in the saxagliptin
treatment groups (Additional file 1). Titration from sax-
agliptin 2.5 to 5 mg q.A.M. gave a small further reduc-
tion in mean (SE) HbA1c (−0.12% [0.072]) and titration
in the other treatment groups (where nearly all patients



































SAXA 2.5 mg q.A.M.
SAXA 5 mg q.A.M.
SAXA 2.5/5 mg q.A.M.
SAXA 5 mg q.P.M.
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= addition of metformin to PBO group at week 24.
Figure 2 Adjusted mean changes from baseline HbA1c over 76 weeks (repeated-measures analysis). Randomized and treated patients.
Patients who received placebo in the short-term period were switched to blinded metformin 500 mg at week 24. Titration of blinded metformin
was not allowed. BL: baseline; HbA1c: glycated hemoglobin; PBO: placebo; SAXA: saxagliptin.
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ing in mean (SE) HbA1c over the 13-week timeframe
(0.09% [0.105], 0.11% [0.086], and 0.02% [0.120] for saxa-
gliptin 5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M.,
respectively).
Mean adjusted changes in glycemic parameters from
baseline to week 76 (repeated-measures analysis) are
shown in Table 3 and Figure 2. The reduction from
baseline HbA1c persisted at week 76 (−0.34% to −0.84%)
but was attenuated to a variable degree in the groups
initially treated with saxagliptin 5 mg q.A.M, 2.5/5 mg q.
A.M., and 5 mg q.P.M. but showed no attenuation in the
group initially treated with saxagliptin 2.5 mg q.A.M. At
week 24 the reduction from baseline HbA1c in the pla-
cebo group (repeated-measures analysis) was −0.33%. In
the control group, which received blinded metformin
500 mg/day from week 24, mean change from baseline
in HbA1c at week 76 was −0.29% (repeated-measures
analysis).
The mean adjusted change from baseline FPG
(repeated-measures analysis) was sustained up to week
76 in the saxagliptin groups originally treated with
2.5 mg q.A.M. and 2.5/5 mg q.A.M., but not in the saxa-
gliptin 5 mg q.A.M. and 5 mg q.P.M. groups (Table 3).The control group, to which metformin had been added
after week 24, consistently showed no change from base-
line FPG throughout the study. The proportion of
patients achieving HbA1c <7% at week 76 was similar to
that at week 24 (Tables 2 and 3). Consistently numeric-
ally greater mean reductions from baseline PPG-AUC
were observed for all saxagliptin groups compared with
the control at week 76 (Table 3).
The percentage of patients who discontinued for lack
of glycemic control or required rescue for meeting pre-
specified glycemic criteria at week 24 was higher in the
placebo group (16.2%) than in the saxagliptin groups
(12.2%, 13.5%, 14.1%, and 11.1% for the saxagliptin
2.5 mg q.A.M., 5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg
q.P.M., respectively). At week 76, the percentages of
patients who discontinued for lack of glycemic control
or required rescue were 37.8% in the control group and
33.8%, 33.8%, 32.4%, and 36.1% in the saxagliptin 2.5 mg
q.A.M., 5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M.
groups, respectively.
For all treatment groups in the short-term period and
long-term extension, there were no clinically meaningful
changes from baseline in either systolic or diastolic
blood pressure. Similarly, there were no clinically
Table 3 Changes in glycemic parameters from baseline to week 76
SAXA 2.5 mg q.A.M. SAXA 5 mg q.A.M. SAXA 2.5/5 mg q.A.M. SAXA 5 mg q.P.M. Control
(n = 74) (n = 74) (n = 71) (n = 72) (n = 74)
HbA1c (%) (repeated measures analysis)
BL, n 67 69 69 70 68
n with observed data at 76 weeks 24 34 28 26 31
BL, mean (SE) 8.0 (0.11) 7.9 (0.11) 8.0 (0.13) 7.9 (0.11) 7.8 (0.11)
Adj mean change from BL, mean (SE) −0.84 (0.122) −0.41 (0.108) −0.60 (0.118) −0.34 (0.117) −0.29 (0.114)
95% CI (−1.07, –0.60) (−0.63, –0.20) (−0.83, –0.37) (−0.57, –0.12) (−0.52, –0.07)
FPG (mg/dL) (repeated measures analysis)*
BL, n 70 71 71 71 72
n with observed data at 76 weeks 20 28 22 23 26
BL, mean (SE) 157 (4.0) 162 (4.2) 171 (6.2) 160 (5.3) 160 (5.5)
Adj mean change from BL, mean (SE) −12 (5.0) −1 (4.4) −15 (4.9) 1 (4.8) 0.1 (4.6)
95% CI (−21.8, –2.1) (−10.1, 7.3) (−24.0, –4.9) (−8.4, 10.3) (−9.0, 9.1)
HbA1c <7.0% (LOCF)
N 67 69 69 70 68
n (%) 27 (40.3) 22 (31.9) 30 (43.5) 22 (31.4) 23 (33.8)
95% CI (28.5, 53.0) (21.2, 44.2) (31.6, 56.0) (20.9, 43.6) (22.8, 46.3)
PPG–AUC (mgmin/dL) (repeated measures analysis)*
BL, n 44 43 41 39 41
n with observed data at 76 weeks 30 35 27 29 33
BL, mean (SE) 47053 (1529.8) 49512 (1621.9) 48084 (1673.4) 44498 (1813.4) 46111 (1938.3)
Adj mean change from BL, mean (SE) −5859 (1498.3) −4163 (1429.2) −8511 (1571.7) −4700 (1547.4) −3788 (1465.6)
95% CI (−8821, –2897) (−6988, –1338) (−11618, –5404) (−7759, –1642) (−6685, –891)
*Value rounded to nearest whole number
Adj: adjusted; BL: baseline; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; LOCF: last observation carried forward; PPG–AUC: postprandial glucose-area
under the curve; SAXA: saxagliptin; SE: standard error
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ment group. With the exception of patients in the saxa-
gliptin 5 mg q.P.M. group (+0.1 kg), a small reduction
from baseline body weight was maintained in all treat-
ment groups (−0.5 to −1.0 kg).
Safety and tolerability
Overall, saxagliptin was generally well tolerated in the
short-term period and long-term extension (Table 4).
The proportion of patients experiencing ≥1 AE was
numerically greater in those receiving saxagliptin
(71.1%) versus control (55.4%). During the short-term
+ long-term period, at the SOC level, the proportion of
patients with AEs was similar in the saxagliptin-treated
patients and patients in the control group, except in
the following SOCs: infections and infestations (41.9%
vs 24.3%); gastrointestinal disorders (23.7% vs 10.8%);
injury, poisoning and procedural complications (16.8%
vs 6.8%); and general disorders and administration site
conditions (15.1% vs 9.5%). For each of these SOCs,
there were no single preferred terms or closely relatedterms that fully accounted for these findings. Saxaglip-
tin was not associated with the development of oppor-
tunistic infections. The most common AEs by
preferred term occurring ≥5% in all saxagliptin treated
patients are listed in Table 4. AEs occurring ≥5% in
any treatment group by preferred term are listed in
Additional file 2.
The incidence of SAEs was generally similar across
treatment groups throughout the study: 8.9% of
saxagliptin-treated patients and 6.8% of control patients.
For saxagliptin, the most common SAE SOC was in-
jury, poisoning and procedural complications (2.1%
saxagliptin, 0% control): 3 of these 6 events were
protocol-mandated SAEs of “overdose.” Two patients
in the saxagliptin group were reported to have an AE
of accidental overdose of what was determined to be
placebo (looking like the metformin taken by control
patients) and the third patient took 5 extra saxagliptin
2.5 mg pills over 14 days. All patients were completely
asymptomatic. For the control group, the most com-
mon SAE SOC was “cardiac” (1.7% saxagliptin, 2.7%
Table 4 Adverse event summary: short-term period and long-term extension
SAXA 2.5 mg q.A.M.
(n = 74)
SAXA 5 mg q.A.M.
(n = 74)
SAXA 2.5/5 mg q.A.M.
(n = 71)






Adverse events n (%)*
≥1 AE 49 (66.2) 54 (73.0) 53 (74.6) 51 (70.8) 207 (71.1) 41 (55.4)
≥1 related AE 17 (23.0) 17 (23.0) 14 (19.7) 10 (13.9) 58 (19.9) 11 (14.9)
Deaths 0 0 2 (2.8) 0 2 (0.7) 0
≥1 SAE 7 (9.5) 8 (10.8) 7 (9.9) 4 (5.6) 26 (8.9) 5 (6.8)
≥1 related SAE 1 (1.4) 0 0 0 1 (0.3) 1 (1.4)
Discontinuation due to AE 4 (5.4) 2 (2.7) 5 (7.0) 1 (1.4) 12 (4.1) 3 (4.1)
Discontinuation due to SAEs 1 (1.4) 0 2 (2.8) 0 3 (1.0) 2 (2.7)
Adverse events (≥5% All SAXA)†
URTI 11 (14.9) 10 (13.5) 11 (15.5) 11 (15.3) 43 (14.8) 7 (9.5)
Nasopharyngitis 3 (4.1) 4 (5.4) 3 (4.2) 5 (6.9) 15 (5.2) 3 (4.1)
Diarrhea 7 (9.5) 4 (5.4) 1 (1.4) 4 (5.6) 16 (5.5) 1 (1.4)
Pain in extremity 2 (2.7) 3 (4.1) 5 (7.0) 5 (6.9) 15 (5.2) 1 (1.4)
Reported hypoglycemia{ 3 (4.1) 6 (8.1) 6 (8.5) 6 (8.3) 21 (7.2) 3 (4.1)
Confirmed hypoglycemia** 0 1 (1.4) 0 1 (1.4) 2 (0.7) 1 (1.4)
Exposure, weeks, mean (SD)*** 54.6 (27.6) 62.2 (24.3) 56.8 (27.2) 59.8 (25.0) − 58.8 (25.8)
*Includes hypoglycemia
†Excludes hypoglycemia
{Reported hypoglycemia was defined as events consistent with signs or symptoms of hypoglycemia with or without documented blood glucose levels
**Confirmed hypoglycemia defined as fingerstick glucose value ≤50 mg/dL in the presence of associated symptoms
***Exposure defined as the time from the first day to the last day, inclusive, that a patient took study medication. Exposure data includes rescue
AE: adverse event; SAE: serious adverse event; SAXA: saxagliptin; SD: standard deviation; URTI: upper respiratory tract infection
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treatment groups included 1 event each of angina pec-
toris, unstable angina, atrial fibrillation, acute cor pul-
monale, and coronary artery disease, and 2 events with
the preferred term of “acute myocardial infarction” in
the control group. The only SAE in the neurological
SOC was a transient ischemic attack in the control
group. Three SAEs in 2 patients were reported as
related to the study drug: 1 patient in the saxagliptin
2.5 mg q.A.M. group presented with cellulitis and
intertrigo, and 1 patient in the control group who had
been previously rescued with metformin in the long-
term extension presented with severe hypoglycemia
which resolved the same day without treatment.
A total of 12 (4.1%) patients treated with saxagliptin
discontinued due to AEs; 3 (1.0%) of these patients dis-
continued due to SAEs. Similarly, 3 (4.1%) patients in
the control group discontinued due to AEs; 2 (2.7%)
patients discontinued due to SAEs. Two deaths occurred
in the saxagliptin 2.5/5 mg q.A.M. group, neither of
which was considered by study investigators to be treat-
ment related. One patient with a history of splenectomy
due to a bull-riding accident died on day 54 due to
pneumococcal sepsis. The second patient, who had ele-
vated alkaline phosphatase at study entry, discontinued
the study on day 13 due to pancreatic carcinoma andlater died on day 502 due to pancreatic carcinoma and
metastatic liver cancer.
The proportion of patients with hypoglycemic AEs
was 4.1%, 8.1%, 8.5%, and 8.3% in the saxagliptin 2.5 mg
q.A.M., 5 mg q.A.M., 2.5/5 mg q.A.M., and 5 mg q.P.M.
treatment groups, respectively, and 4.1% in the control
group. There were 2 cases of confirmed (defined as fin-
gerstick glucose ≤50 mg/dL with associated symptoms)
mild hypoglycemia in saxagliptin-treated patients, and 1
case of confirmed hypoglycemia in the control group re-
ceiving metformin (this was not the patient in the con-
trol group noted previously with the hypoglycemia SAE).
Prespecified “acute cardiovascular AEs” [9], which in-
clude myocardial infarction and other patient important
CV events, were reported in 2 patients treated with sax-
agliptin (0.7%) and 3 with control (4.1%). The overall
incidences of marked laboratory abnormalities were
similar in all treatment groups. Other laboratory para-
meters, including hematologic, hepatic, and renal safety
tests, showed no drug-related signal (data not shown).
There were no clinically relevant changes in electrocar-
diograms or vital signs (data not shown).
Discussion
In treatment-naïve patients with T2DM, once-daily saxa-
gliptin lowered blood glucose concentrations relative to
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through week 76 in all treatment groups. These findings
were largely similar to those reached in the previously
published saxagliptin monotherapy trial [3]. However, it
is noteworthy that this study also explored the effects of
dose titration and P.M. versus A.M. dosing, and that the
patient populations differed with respect to important
baseline characteristics (including baseline CV risk,
HbA1c, and FPG).
At week 24, adjusted mean changes from baseline
HbA1c demonstrated in the 4 saxagliptin treatment groups
(−0.61% to −0.71%) were comparable and consistent. The
adjusted mean change from baseline HbA1c of −0.26% in
the placebo group was larger, however, than that seen in
the previous study of saxagliptin as monotherapy (+0.19%)
[3]. Per study protocol, patients received exercise and diet-
ary instruction throughout the study. The reduction in
HbA1c observed in the placebo group, and the reduction
in body weight in all groups, largest in placebo (−1.3 kg
[0.40]), supports the notion that the dietary and exercise
interventions (as per local guidelines) were followed by
patients in this group. Adherence to diet and exercise
interventions in the context of low HbA1c and FPG
(at baseline 7.9% and 162 mg/dL, respectively) may
have also lessened the placebo-subtracted HbA1c reduc-
tion observed, particularly given the glucose-dependent
mechanism of action of DPP-4 inhibitors [10].
The reduction in HbA1c from baseline to week 24
observed in all treatment groups was sustained through
week 76 in the saxagliptin 2.5 mg q.A.M. and 2.5/5 mg
q.A.M. treatment groups. The saxagliptin 5 mg q.A.M.
and 5 mg q.P.M. groups, which maintained a higher pro-
portion of patients who completed without titration
(17.9%–26.4%) than the saxagliptin 2.5 mg groups
(9.3%–13.7%), showed reductions from baseline HbA1c
at week 76 that were smaller than those at week 24. The
control group, which started metformin treatment at
week 24, showed an expected HbA1c reduction from
week 24 to week 30 likely due to the addition of active
medication but this effect attenuated thereafter. The
small number of patients per treatment group and the
decreasing amount of available data prior to rescue over
time limits the ability to draw definitive conclusions
about efficacy results at the end of the long-term period.
The reason for the upward HbA1c trend in the arms ran-
domized to saxagliptin 5 mg or placebo is not clear; we
can only speculate that it may represent attenuation of
the diet and exercise effect documented in the placebo
arm during the first 24 weeks and/or natural progression
of type 2 diabetes [11]. The fact this trend was not obvi-
ous in the 2 arms randomized to 2.5 mg may represent
the small effect of titration to 5 mg (Additional file 1).
The 2010 European Medicines Agency draft guidance
for drugs for the treatment of diabetes recommends thatnew therapies be studied in a titration design [12]. In
this study, saxagliptin was given as a fixed dose as well
as in titration in the first 24 weeks, with all patients eli-
gible for titration in the long-term extension. Decreases
in HbA1c were seen in all saxagliptin treatment groups
at both the 2.5 and 5 mg doses, and regardless of
whether saxagliptin was given in the morning or evening
or in a titrated fashion. A small, additional HbA1c reduc-
tion was identified with titration of saxagliptin from 2.5
to 5 mg; however, no additional HbA1c reductions were
observed with titration of saxagliptin from 5 to 10 mg in
the long-term extension. This finding is consistent with
other studies, which demonstrated similar efficacy for
saxagliptin doses of 5 and 10 mg [4,13]. Dosing saxaglip-
tin 5 mg in the morning resulted in the highest rates of
completion and completion without rescue of any treat-
ment group, factors which are likely to be most attract-
ive for many physicians. Importantly, treatment with
saxagliptin 2.5 mg with eligibility for early titration to
5 mg did not appear to confer any benefit on safety or
tolerability. We found that saxagliptin is generally well
tolerated and effective given in titration, but this study
does not suggest any advantages to early titration over
an initial 5 mg fixed dose.
This study also examined dosing of saxagliptin at dif-
ferent times of the day. The treatment groups initially
given saxagliptin 5 mg in the evening showed a decrease
from baseline HbA1c that was similar to that in the
group initially treated with saxagliptin 5 mg q.A.M., by
repeated-measures analysis at weeks 24 and 76. While
the FPG results with evening dosing did not reach statis-
tical significance, the magnitude of effect was generally
similar to those in the other active treatment groups,
and the lack of significance may reflect the relatively
small numbers of patients per treatment group. Overall,
patients in the saxagliptin 5 mg q.P.M. group had a dis-
position and safety profile very similar to the other saxa-
gliptin treatment groups.
Saxagliptin was well tolerated. While the proportion of
patients experiencing AEs was numerically higher in the
saxagliptin groups compared with control the rates of
SAEs and AEs leading to discontinuation were similar
between saxagliptin-treated and control patients. The
overall AE profile observed at week 76 was similar to
that seen at week 24. It is important to note that the
relatively modest numbers of patients within each treat-
ment group likely contributed to some variability in AE
incidence rates.
Trials with lower CV risk patients such as the UK Pro-
spective Diabetes Study (UKPDS) [14] and the Kuma-
moto study [15], and those with higher risk patients
such as the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) [16] and Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified
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have consistently shown a benefit of lower glucose on
microvascular complications. However, the anticipated
benefit on macrovascular events based on UKPDS lower
risk patients [18] was not observed in these studies
enriched in patients at higher CV risk. The American
Association of Clinical Endocrinologists/American Col-
lege of Endocrinology [19], ADA [20], and ADA/Euro-
pean Association for the Study of Diabetes [21]
guidelines have recently been updated in response, and
each emphasizes that hypoglycemia may be a greater risk
than previously appreciated, especially in patients at high
CV risk. They also suggest that the risk profile of drugs
and glycemic targets may be different for populations at
higher CV risk. For saxagliptin, the results of this trial in
a population at higher baseline CV risk are consistent
with the earlier reported monotherapy trial, in which the
patient population had a lower baseline CV risk. The
overall saxagliptin registrational program did not suggest
that saxagliptin was associated with increased CV risk
[9]. A large CV outcome trial to investigate the possible
benefit of saxagliptin on CV events is currently ongoing
(ClinicalTrials.gov Identifier: NCT01107886).
Study limitations include the relatively modest size of
the treatment groups, which introduces a greater risk
that apparent differences between groups are due to
chance. Use of rescue therapy ensured that patients
received needed glycemic control. However, it compli-
cates the interpretation of efficacy findings. To avoid the
confounding effects of rescue therapy efficacy results
included only data collected up to the time of rescue,
such that fewer patients were able to contribute data for
efficacy analyses at later time points in the study. Be-
cause of the small number of patients with available effi-
cacy data at later time points, the long-term efficacy
results should be interpreted with caution. The long-
term extension control group included patients who
received blinded metformin to ensure that patients in
the study did not experience overly prolonged periods
without antihyperglycemic medication. While necessary
for patient well-being, this addition limits the ability to
draw firm, placebo-based conclusions with respect to ef-
ficacy in the long-term. Finally, there was reduced ability
to draw conclusions regarding the PPG-AUC analysis,
due to an error in OGTT administration to several
participants.Conclusions
In conclusion, saxagliptin monotherapy demonstrated
HbA1c reductions at 24 weeks, regardless of time of day
of administration, and was generally well tolerated for
up to 76 weeks, with a low incidence of hypoglycemia
across treatment groups.Additional files
Additional file 1: HbA1c changes from time of first titration in the
long-term extension to 13 weeks after time of titration.
Additional file 2: Table summarizing adverse events occurring
in≥ 5% in any treatment group during the short-term period and
long-term extension.
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